European Marketing Authorization Application for velaglucerase alfa for the treatment of type 1 Gaucher diseaseShire plc , the global specialty biopharmaceutical company, today announced that it one MAA submitted, the European Medicines Agency for velaglucerase alfa, the company enzyme replacement therapy in development for the treatment of type 1 Gaucher disease. This is the third filing for velaglucerase alfa that has been submitted, with previous entries in the United States and Canada.
Gaucher disease has classically categorized into 3 clinical types. Type 1 is the most common, it is distinguished from Type 2 and Type 3 by the lack of early neurological symptoms. Type 1 Gaucher disease is characterized by variability in signs, symptoms, severity and progression.. In Europe and other countries outside of the U.S. Patients continue to velaglucerase alfa through pre-approval access programs that were developed in partnership with national and regional authorities and especially to the continuing shortage of address lists obtained in the U.S., continue to patients in an FDA – approved treatment protocol, which is open to to be added since September 2009. Gaucher disease is the most common LSD.There were plenty of surgery techniques for reconstructing the vaginal but if I view began to those patient I thought to natural-looking natural-looking and lack in many instances, said Dr. Director Sarah M. And Charles E. Seay the Center for Pediatric Urology. Too many suffering with complications of from these types of vaginal reconstruction of, often resulting at pain during sexual intercourse adult. .